Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events
Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events
复制标题
DOI：
10.2165/11631570-000000000-00000
复制
发表时间：
2012-01-01
期刊：
影响因子：
6.8
通讯作者：
Biondi-Zoccai, Giuseppe G. L.
中科院分区：
文献类型：
--
作者：
Abbate, Antonio;Van Tassell, Benjamin W.;Biondi-Zoccai, Giuseppe G. L.
动脉粥样硬化的炎症假说认为斑块内的炎症促进斑块进展和并发症。白细胞介素-1（IL-1）是一种关键的促炎细胞因子，负责损伤后炎症反应的放大。动物研究表明，IL-1阻断剂可有效限制动脉粥样硬化和动脉粥样硬化血栓形成，并改善急性心肌梗死和缺血性卒中的结局。在急性心肌梗死、缺血性中风和心力衰竭患者中的初步数据是有希望的。目前正在既往急性心肌梗死患者中进行一项canakinumab的大型二级预防试验。关于IL-1阻断剂的最佳使用和首选药物，仍有许多悬而未决的问题。
The inflammatory hypothesis of atherosclerosis postulates that inflammation within the plaque promotes plaque progression and complications. Interleukin-1 (IL-1) is a key pro-inflammatory cytokine responsible for the amplification of the inflammatory response following injury. Animal studies show that IL-1 blockade is effective in limiting atherosclerosis and atherothrombosis and improving outcomes in acute myocardial infarction and ischemic stroke. Preliminary data in patients with acute myocardial infarction, ischemic stroke, and heart failure are promising. A large secondary prevention trial with canakinumab in patients with prior acute myocardial infarction is currently ongoing. Many unanswered questions remain regarding the optimal use of IL-1 blockade and the preferred agent.